U.S. markets open in 5 hours 42 minutes

Navidea Biopharmaceuticals to Present at 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith

DUBLIN, OH / ACCESSWIRE / May 7, 2018 / Navidea Biopharmaceuticals (NYSE American: NAVB) ("Navidea" or "the Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will present at the 3rd Annual Disruptive Growth & Healthcare Conference in New York, NY being held May 8-9, 2018. Michael Goldberg, Chief Financial and Operating Officer, will be giving a corporate presentation focused on Navidea's clinical programs.

Event: 3rd Annual Disruptive Growth & Healthcare Conference

Presentation Date: Tuesday, May 8, 2018

Presentation Time: 2:35pm EST

Location:ReedSmith Offices, New York, NY

The 2018 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.

To schedule a meeting with Navidea management at the conference, please contact Navidea Investor Relations at tpatel@edisongroup.com.

About RHK Capital:

Advisory Group Equity Services, Ltd. (dba RHK Capital) was founded in 1984. RHK Capital is a boutique investment banking firm specializing in small to medium-sized transactions. RHK is led by a management team with extensive financial industry experience and a desire to provide companies and individuals with the tools and expertise to accomplish their financial goals. In addition to investment banking, RHK has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, investment management, mortgages, and business lending. As a division of Advisory Group Equity Services (AGES), all securities are offered through Advisory Group Equity Services Ltd., a registered broker-dealer, member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corporation.

About TAG Group:

AGES as part of the holding company TAG Group, Inc., is a leading provider of estate, business and financial services for high net worth individuals and business entities. TAG maintains a comprehensive network of legal, financial and accounting professionals who are committed to providing the highest level of service to their clients. TAG maintains three separate and distinct operating units under its corporate umbrella, they are: Trust Advisory Group, Ltd., Advisory Group Equity Services, Ltd., and Estate Insurance Services, Ltd.

About ReedSmith:

Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. Our long-standing relationships and international outlook make us the go-to partner for speedy resolution of complex transactions, disputes and regulatory matters. At Reed Smith, we believe that the practice of law has the ability to drive progress. We know your time is valuable and your matters are important. We are focused on outcomes, are highly collaborative, and have deep industry insight that, when coupled with our local market knowledge, allows us to anticipate and address your needs. You deserve purposeful, highly engaged client service that drives progress for your business.

For those interested in attending, please visit www.DisruptNYC.com for more information.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts.

For more information, please visit www.navidea.com.

Contacts

Navidea Biopharmaceuticals, Inc.
Jed Latkin, 614-551-3416
CFO/COO
jlatkin@navidea.com

or

Edison Advisors
Tirth Patel, 646-653-7035
Vice President, Investor Relations
tpatel@edisongroup.com

SOURCE: Navidea Biopharmaceuticals